About FDA

Office of Pharmaceutical Quality

CDER’s Office of Pharmaceutical Quality’s (OPQ) mission is to assure that quality medicines are available for the American public.

What OPQ Does

OPQ is a new office within CDER that creates a single unit dedicated to product quality.  The new structure, which stood-up in January 2015, provides better alignment among all drug quality functions at CDER, including review, inspection, and research.

OPQ combines non-enforcement-related drug quality work into one super-office, creating one quality voice and improving our oversight of quality throughout the lifecycle of a drug product. OPQ creates a uniform drug quality program across all sites of manufacture, whether domestic or foreign, and across all drug product areas – new drugs, generic drugs, and over-the-counter drugs.

This organizational structure, along with new processes and policies, supports our mission to ensure that safe, effective, high quality drugs are available for the American public.

The changes that established OPQ include the following offices:

Office of Pharmaceutical Quality Offices and Leadership

The following individuals serve as office leaders:

Director: Michael Kopcha, Ph.D., R.Ph.
Deputy Director: Lawrence Yu, Ph.D.

  • Office of Program and Regulatory Operations (OPRO): Giuseppe Randazzo (Acting)
  • Office of Policy for Pharmaceutical Quality (OPPQ): Ashley Boam (Acting)
  • Office of Biotechnology Products (OBP): Director: Steve Kozlowski
  • Office of New Drug Products (ONDP): Sarah Pope Miksinski (Acting)
  • Office of Lifecycle Drug Products (OLDP): Susan Rosencrance (Acting)
  • Office of Testing and Research (OTR): Director: Lucinda (Cindy) Buhse
  • Office of Process and Facilities (OPF): Robert Iser (Acting)
  • Office of Surveillance (OS): Russell Wesdyk (Acting)

 

OPQ Guidances on the FDA Website

OPQ Guidances on the FDA Website

CategoryTitleTypeDate
Pharmaceutical Quality/CMC Advancement of Emerging Technology Applications to Modernize the Pharmaceutical Manufacturing Base; Draft Guidance for Industry; Availability (PDF - 63KB) Draft Guidance 12/23/15
Pharmaceutical Quality/CMC Liposome Drug Products: Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation (PDF - 146KB) Draft Guidance 10/29/15
Pharmaceutical Quality/CMC Selection of the Appropriate Package Type Terms and Recommendations for Labeling Injectable Medical Products Packaged in Multiple-Dose, Single-Dose, and Single-Patient-Use Containers for Human Use (PDF - 113KB) Draft Guidance 10/21/15
Pharmaceutical Quality/CMC Botanical Drug Development: Guidance for Industry (PDF - 227KB) Draft Guidance 08/14/15
Biopharmaceuticals Dissolution Testing and Specification Criteria for Immediate-Release Solid Oral Dosage Forms Containing Biopharmaceutics Classification System Class 1 and 3 Drugs Guidance for Industry (PDF - 87KB) Draft Guidance 07/31/15
Pharmaceutical Quality/CMC and Pharmaceutical Quality/CGMP Request for Quality Metrics Guidance for Industry (PDF - 250KB) Draft Guidance 07/27/15
Pharmaceutical Quality/CMC Analytical Procedures and Methods Validation for Drugs and Biologics (PDF - 134KB) Final Guidance 07/24/15
Pharmaceutical Quality/CMC Allowable Excess Volume and Labeled Vial Fill Size in Injectable Drug and Biological Products (PDF - 77KB) Final Guidance 06/24/15
Pharmaceutical Quality/CMC Size, Shape, and Other Physical Attributes of Generic Tablets and Capsules (PDF - 89KB) Final Guidance 06/18/15
Labeling Naming of Drug Products Containing Salt Drug Substances (PDF - 210KB) Final Guidance 06/16/15
Pharmaceutical Quality/CMC Established Conditions: Reportable CMC Changes for Approved Drug and Biologic Products Guidance for Industry (PDF - 165KB) Draft Guidance 05/29/15
Biopharmaceutics Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. (PDF - 141KB) Draft Guidance 05/05/15
Pharmaceutical Quality/CMC Environmental Assessment: Questions and Answers Regarding Drugs With Estrogenic, Androgenic, or Thyroid Activity (PDF - 69KB) Final Guidance 03/04/16
Pharmaceutical Quality/CMC Development and Submission of Near Infrared Analytical Procedures (PDF - 176KB) Draft Guidance 03/30/15

Page Last Updated: 01/22/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.